Discussion The incidence of MRONJ in the UK is 620 per year. At the time of treatment, we
reviewed 11 case reports, two case series and one retrospective study using teriparatide to …

Medication-related osteonecrosis of the jaw (MRONJ) is a potentially severe adverse side
effect of antiresorptive agents. However, withdrawal of such agents in patients with …

Medication-related osteonecrosis of the jaw (MRONJ) is a painful and intractable disease of
the jaw that clinically presents as an area of ulceration with exposed necrotic bone. In …

Background Therapeutic strategies for patients with medication-related osteonecrosis of the
jaw (MRONJ) remain controversial. The aim of the present study was to clarify the …

Introduction Medication‐related osteonecrosis of the jaw (MRONJ) is uncommon but can
result in severe destruction of the jaw. This case–control study investigated the therapeutic …

We studied the effectiveness of teriparatide (TPTD) for treating medication-related
osteonecrosis of the jaw (MRONJ) in patients with osteoporosis and examined differences in …

Objectives To integrate the data published on the effect of teriparatide (TPTD) therapy on
cases of medication-related osteonecrosis of the jaw (MRONJ) in a comprehensive analysis …

Medication-related osteonecrosis of the jaw (MRONJ) is a complex disease which can be
associated with multiple morbidities and is challenging to treat. This review evaluates the …

Considering the lack of studies determining the real TPTD efficacy in individuals who
develop MRONJ, our objective was to combine the available data on MRONJ cases treated …

PURPOSE Medication-related osteonecrosis of the jaw (MRONJ) is an infrequent but morbid
and potentially serious condition associated with antiresorptive and antiangiogenic …